Concepts in in vivo siRNA delivery for cancer therapy
- 23 April 2009
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 220 (2), 285-291
- https://doi.org/10.1002/jcp.21790
Abstract
In vivo gene silencing using RNAi plays an important role in target validation and is advancing towards the development of RNAi‐based therapeutics. RNAs were thought to have just two broad functions in cells as messenger RNAs (mRNAs) and ribosomal RNAs, but recently the relevance of microRNAs is becoming more clearly understood. mRNA molecules transmit information between DNA and protein and, as such, are vital intermediaries for gene expression. Ribosomal and transfer RNAs have structural, catalytic, and information‐decoding roles in the process of protein synthesis, whereas microRNAs are regulators of gene expression. This review presents the early and intriguing successes of using siRNAs for in vivo gene silencing and its use as a possible cancer therapeutics. J. Cell. Physiol. 220: 285–291, 2009.Keywords
This publication has 96 references indexed in Scilit:
- Antibody-Mediated Targeting of siRNA via the Human Insulin Receptor Using Avidin−Biotin TechnologyMolecular Pharmaceutics, 2008
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences, 2007
- Retracted: RNAi‐mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease‐9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growthInternational Journal of Cancer, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- Optimization and characterization of tRNA-shRNA expression constructsNucleic Acids Research, 2007
- shRNA and siRNA delivery to the brainAdvanced Drug Delivery Reviews, 2007
- Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1Proceedings of the National Academy of Sciences of the United States of America, 2007
- Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growthNeuron Glia Biology, 2004
- siRNAs: applications in functional genomics and potential as therapeuticsNature Reviews Drug Discovery, 2004
- RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinomaOncogene, 2004